[go: up one dir, main page]

WO2010119088A2 - Lait et produits lactés modifiés pour présenter un indice insulinémique réduit et/ou une activité mitogène réduite - Google Patents

Lait et produits lactés modifiés pour présenter un indice insulinémique réduit et/ou une activité mitogène réduite Download PDF

Info

Publication number
WO2010119088A2
WO2010119088A2 PCT/EP2010/054937 EP2010054937W WO2010119088A2 WO 2010119088 A2 WO2010119088 A2 WO 2010119088A2 EP 2010054937 W EP2010054937 W EP 2010054937W WO 2010119088 A2 WO2010119088 A2 WO 2010119088A2
Authority
WO
WIPO (PCT)
Prior art keywords
milk
igf
insulin
activity
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/054937
Other languages
English (en)
Other versions
WO2010119088A3 (fr
Inventor
Bodo Melnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2010119088A2 publication Critical patent/WO2010119088A2/fr
Publication of WO2010119088A3 publication Critical patent/WO2010119088A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1209—Proteolytic or milk coagulating enzymes, e.g. trypsine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/148—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by molecular sieve or gel filtration or chromatographic treatment
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitoqenic activity
  • the present invention relates to processes for treating milk and milk products obtainable by the treatment which will not be able to induce insulin resistance and/or exhibit a reduced insulinemic index and/or reduced mitogenic activity
  • Insulin/IGF-1 signalling is involved in the regulation of fetal growth, T-cell maturation in the thymus, linear growth, pathogenesis of acne, atherosclerosis, diabetes mellitus, obesity, cancer and neurodegenerative diseases, thus affecting most chronic diseases of Western societies.
  • milk intake during pregnancy adversely affects the early fetal programming of the IGF-I axis which will influence health risks later in life.
  • An accumulated body of evidence for the adverse effects of cow's milk consumption from fetal life to childhood, adolescence, adulthood and senescence will be provided which strengthens the presented hypothesis.
  • GH-IGF-1-axis somatotropic axis
  • a modified cow milk or milk of another milk-giving species should be used which has by treatment not the ability to induce insulin resistance, i.e., this modified milk is not able to interfere with the GH-IGF-1-axis and will not increase human GH, insulin and IGF-I serum levels.
  • Special targets for inactivation are bovine alpha- Lactalbumin and alpha-Lactalbumin of other species used for milk production for humans.
  • Insulin and the insulin-like growth factor system are insulin-like growth factor system
  • the insulin-like growth factor (IGF) system is essential for normal embryonic and postnatal growth, and plays an important role in the function of a healthy immune system, lymphopoiesis, myogenesis and bone growth among other physiological functions.
  • Growth hormone (GH) and IGFs play an important role in growth and tissue homeostasis.
  • GH secreted by the anterior pituitary binds to GH-receptor, expressed on most peripheral cells of the body. In peripheral tissues and predominantly in the liver, GH induces the synthesis and secretion of the 7.65 kDa polypeptide hormone IGF-I, the mediator of the growth stimulating activity of GH.
  • IGFBP-3 IGF-binding protein-3
  • IGFBP-2 IGF-binding protein-3
  • IGFBP-2 IGF-binding protein-3
  • IGFlR IGF-1-receptor
  • IR insulin receptor
  • IGF-2 binds to IGF-2-receptor (IGF2R), a scavenger receptor down-regulating IGF-2.
  • IGF-2 is also able to bind to IGFlR.
  • Insulin primarily binds to IR-A and IR-B, but also binds with lower affinity to IGFlR.
  • IGF-I and IGF-2 bind to IR with lower affinity ( Figure 1).
  • IGFlR signal transduction is mediated primarily by the activation of the Ras-Raf-MAP kinase pathway and the phosphoinositide 3-kinase (PI3K)/Akt pathway.
  • IGF-I acts a strong mitogen inducing cell growth and proliferation, but inhibits apoptosis [I].
  • the IR-B isoform is the form best known for the classic metabolic responses induced upon insulin binding and this isoform has low affinity for IGFs [I].
  • the IR-A isoform arises from alternative splicing of exon 11 encoded by the IR gene. Activation of the IR-A by insulin or IGF-2 leads to mitogenic responses similar to those described for IGFlR. Increased signaling via IR-A has been associated with the development of cancer [2]. In this regard, insulin and IGF-2 signal transduction via IR-A and IGF-I signaling via IGFlR induce and amplify mitogenic responses (Figure 1).
  • Cow's milk and dairy products derived from milk are widely consumed by children and adults of Western societies well after the age of weaning. It is important to note that cow's milk contains active IGF-I (4-50 ng/ml) and IGF-2 (40-50 ng/ml) [3, 4].
  • IGF-signaling belongs to the canonical pathways and networks regulated by estrogen and placental GH in the bovine mammary gland. Cows treated with recombinant bovine GH to improve milk yield showed increased levels of IGF-I in the milk [4]. High levels of IGF-I are still detectable after pasteurization and homogenization of milk [5]. Intriguingly, bovine and human IGF-I share the same amino acid sequences and therefore bovine IGF-I can bind to the human IGFlR [6].
  • IGFs in milk can survive digestion and remain bioactive in the serum of milk consumers.
  • Intestinal absorption of growth factors in milk may be increased by Western diet which is high in wheat products and potatoes. It has been recognized that wheat-derived gluten and potato-derived glycoalkaloids perturb and increase intestinal permeability resulting in increased intestinal protein absorption [6a, 6b, 6c].
  • Fermented and non-fermented milk products give rise to insulinaemic responses far exceeding what could be expected from their low glycaemic indexes (GI). Despite low GIs of 15 to 30, milk products produce three- to sixfold higher insulinaemic indexes (II) of 90-98 [17].
  • II insulinaemic indexes
  • casein The major protein fractions of cow's milk is casein (80%), the remaining 20% are whey proteins. Both, whey and casein contain specific proteins and peptides that may have growth stimulating effects.
  • the effect of whey and casein fractions of milk on fasting concentrations of IGF-I and insulin has been examined in 57 eight-year-old boys who received over seven days either casein or whey protein fractions with protein amounts of casein or whey similar to the content of 1.5 I skim milk.
  • serum IGF-I increased by 15%, whereas there was no change in fasting insulin.
  • whey group fasting insulin increased by 21%, with no change in IGF-I [23, 24, 24a].
  • whey proteins induce high GIP responses of enteroendocrine intestinal L-cells promoting insulin secretion of pancreatic beta-cells [25a, 25b]. GIP receptors are also expressed on adipocytes and stimulate adipogenesis [25c]. The whey protein-GIP signaling due to milk consumption will thus increase pancreatic insulin secretion and GIP-mediated adipocyte proliferation and differentiation promoting the development of obesity [25c]. Whey proteins further induce cholecystokinin (CCK) from intestinal I-cells [Hall WL et al. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 2003; 89: 239].
  • CCK cholecystokinin
  • a typical "Western" combination diet composed of milk proteins and food with high glycaemic index will have potentiating effects on serum insulin, IGF-I, GLP-I and GIP- levels thereby promoting anabolic signaling pathways involved in mitogenesis and antiapoptosis.
  • Insulin induces hepatic synthesis and secretion of IGF-I
  • the main source of circulating IGF-I is considered to be the liver.
  • Mean serum baseline levels of IGF-I in arterial blood (166 ⁇ g/l) and hepatic vein (160 ⁇ g/l) blood increased during the 180 min of insulin infusion to 183 ⁇ g/l and 185 ⁇ g/l, respectively [26].
  • insulin infusion raised serum IGF-I levels by approximately 13%.
  • IGF-I and IGF-2 are expressed in fetal tissues from the earliest stage of pre-implantation to the final phase of tissue maturation before birth.
  • IGF-2 is the primary growth factor supporting embryonic growth, with IGF-I increasing in importance later in gestation.
  • Concentrations of IGF-I in the fetus are affected by nutrient supply to the fetus and nutrient-sensitive hormones [27]. Insulin positively regulates IGF-I levels [28].
  • one of 10 newborns is affected with fetal macrosomia which has been associated with an increased risk of developing diabetes type 2 later in life. Milk consumption during pregnancy has been associated with a higher birth weight of the offspring [29, 30].
  • Levels of IGF-I and IGFBP-3 appear to be regulated by several factors, such as insulin, GH and maternal factors [31].
  • Levels of IGF-I in cord sera of newborns small for gestational age (mean 48.7 ng/ml) were lower than those of newborns appropriate for gestational age (AGA) (56.4 ng/ml).
  • AGA adultborns large for gestational age (LGA) exhibited the highest IGF-I cord sera levels (96.1 ng/ml) [31].
  • a recent study showed significantly higher insulin, leptin, IGFBP- 3, and glucose concentrations in asymmetric LGA newborns than in symmetric LGA and AGA newborns [32].
  • Macrosomic neonates of diabetic mothers have significantly increased aortic intima-media thickness with higher serum IGF-I, IGFBP-3 and leptin concentrations than those of controls [33].
  • Umbilical cord serum IGF-I levels were correlated significantly with the IGF-I concentrations of the mothers [34].
  • Umbilical cord serum levels of free IGF-I, total IGF-I, IGFBP-2 and leptin have been demonstrated as predictors of birth weight [35].
  • Recently, normal variations in maternal glycaemia on birth size and birth outcomes has been investigated in nondiabetic mothers [36].
  • the GH-IGF-I axis is closely related to feeding in the newborn [37]. More recent data point to an early programming of the IGF-I axis within the first months of live. In early pregnancy maternal endocrine IGF-I programs the placenta for increased functional capacity throughout gestation [38]. IGFs play a critical role in fetal and placental growth throughout gestation [27, 39]. Increased maternal milk consumption during pregnancy enhances the nutrient supply for the fetus by an enlarged placenta. In the guinea pig administration of IGF-I during early pregnancy increased placental transport of glucose and amino acids and increased placental and fetal weights [38].
  • the breastfed infants showed an increased IGF-I level of 328 ⁇ 78.5 in comparison to decreased IGF-I levels of 292.9 ⁇ 95.0 of not breast-fed adolescents of the same age [40].
  • IGF-I axis is programmed early in life [40].
  • milk protein consumption during pregnancy is associated with increased serum levels of IGF-I and postprandial hyperinsulinaemia, a milk protein-mediated shift of the IGF-I axis to higher levels has to be expected early in pregnancy.
  • One of the first effects of milk consumption during early pregnancy might increase maternal IGF-I levels which program the placenta for increased functional capacity throughout gestation thereby increase the risk of fetal macrosomia and other IGF-I- dependent diseases [38].
  • the GH-IGF-I axis plays an important role for the ACTH-dependent production of dehydroepiandrosterone sulphate (DHEAS) of the human adrenal gland [44].
  • DHEAS dehydroepiandrosterone sulphate
  • IGF-I is involved in ovarian androgen synthesis and has been implicated in the pathogenesis of ovarian hyperandrogenism and polycystic ovary syndrome (PCOS) [45].
  • IGF-I serum levels are increased in patients with PCOS who exhibit insulin resistance, anovulation, hyperandrogensism with acne and hirsutism. Proliferation and differentiation of adult testicular Leydig cells is the prerequisite for the increase of circulating plasma androgens during puberty.
  • IGF-I is an essential local mediator of testicular steroidogenesis. In human testicular cell cultures, IGF-I stimulated testosterone secretion and cell proliferation, whereas apoptosis was inhibited [46]. Both insulin and leptin are thought to accelerate the timing of pubertal onset and to up-regulate the tempo of pubertal progression [47, 48]. The insulin sensitizing agent metformin decreases elevated serum IGF-I levels in patients with PCOS [49]. Girls with precocious pubarche and low birth weight reveal increased IGF-I serum levels and insulin resistance which leads to rapid progression of puberty. These girls are predisposed to develop PCOS [50].
  • Metformin treatment (425 mg/day) over two years of eight-year-old girls with precocious pubarche and low birth weight prevented the onset of early puberty by 0.4 years and significantly decreased serum levels of IGF-I, fasting insulin, DHEAS and testosterone [51].
  • Acne is regarded as an androgen-dependent disease of the pilosebaceous follicle. Its course, however, corresponds less closely to plasma androgen levels than it does to GH and IGF-I levels [53]. Significantly increased serum levels of IGF-I have been observed in women with post-adolescent acne as well as adult acne patients [54, 55]. In women, the total number of acne lesions correlated with serum IGF-I levels. In Western societies, acne is a nearly universal disease afflicting 79 to 95% of the adolescent population. In men and women older than 25 years, 40% to 54% have some degree of facial acne, and clinical facial acne persists into middle age in 12% of women and 3% of men [56].
  • the IGF-I axis may be programmed by diet early in infancy [40]. An inverse relation between IGF-I levels during the first months of life and IGF-I levels in adulthood could be observed in 109 infants of the observational Copenhagen cohort study [40]. Low levels of IGF-I in the postnatal period are associated with high IGFl-levels in adolescence. Low levels of IGF-I are reported in SGA newborn infants [34]. Low birth weight is a recognized risk factor for the development of type 2 diabetes and hypertension in adulthood [74, 75].
  • IGF-I receptors are up- regulated by angiotensin II [78].
  • IGF-I mRNA and protein expression and IGF-I plasma levels in hypertensive patients have been related to pressure load [79, 80].
  • mice indicate a significant link between early postnatal diet, somatotropic development, and specific late onset diseases in mice.
  • IGF-I may play a role in modulating hypothalamic stimulation of the developing somatotropic function [8Oa].
  • IGF-I is a known mitogenic hormone that stimulates growth, differentiation and metabolism in a variety of cell types [81]. IGF-I participates in the regulation of the cell cycle, inhibiting the processes of apoptosis and stimulating cell proliferation. IGF-I is a potential tumor promoter [82]. Several studies demonstrated a link between increased IGF-I serum levels with increased risk of breast, prostate, colorectal, and lung cancer [83]. High expression of IGFlRs has been detected in the majority of human cancers. Several studies have confirmed that IGF-I serum levels are related to premenopausal breast density, one of the strongest known breast cancer risk factors believed to represent epithelial and stromal proliferation [84-86].
  • a higher risk for cervical, ovarian and endometrial cancer is related to high IGF- 1 levels in post- and premenopausal women [87].
  • Plasma IGF-I levels and inherited variation in IGF-I have been implicated to be a risk factor in prostate carcinoma [88-90].
  • a high intake of dairy products and calcium has been associated with an increased risk of prostate cancer in a recent meta-analysis [91].
  • IGF-I and insulin act through the tyrosine kinase growth factor signaling cascade enhancing tumor cell proliferation [92].
  • Higher serum IGF-I in older men has been associated with increased risk of cancer death, independent of age, adiposity, lifestyle, and cancer history [92a].
  • IGF-1-dependent T-cell maturation in the fetal thymus might affect the immune system's capacity to handle anti-tumor mechanisms later in life. Thus, fetal macrosomia could have a fatal outcome later in life.
  • Individuals affected by genetic variations in the expression of IGF-I resulting in high IGF- 1 serum levels are at increased risk for cancer. Absence of the IGFl 19-CA repeat allele has been associated with high IGF-I levels during oral contraceptive use in nulliparous women in four different ethnic groups [102]. The IGFl 19-CA repeat allele modifies IGF-I levels, breast volume and possibly early-onset breast cancer risk after hormone exposure in young high- risk women [103, 104].
  • IGF-I is involved in stimulating atherosclerosis [108, 109].
  • IGFlRs are abundant in vascular smooth muscle cells and factors that stimulate atherosclerosis, such as angiotensin II up-regulate IGFlR expression [HO].
  • IGF-I secreted by activated monocytes can stimulate smooth muscle cell proliferation and extracellular matrix synthesis which lead to enlargement of the developing atheroma [111]. It is conceivable, that the relative small IGF-I polypeptide diffuses from the plasma into the early atheromatous lesions. In this regard, milk-derived IGF-I augments local IGF-1-dependent atherogenic effects.
  • the major risk factor for the development of neurodegenerative disease is aging [112]. Mechanistic links between the aging process and toxic protein aggregation, a common hallmark of neurodegenerative diseases, has been revealed. Lifespan is regulated by at least three different mechanisms, one of which is the insulin/IGF-1 signaling pathway. The insulin-IGF-1 pathway is the major candidate to link aging, proteotoxicity and late-onset neurodegenerative disease [113, 114]. It has been suggested that reducing insulin-IGF-1 signaling in the brain will enable cells to maintain the activity of protein quality-control mechanisms and clearance capabilities to a later age, thereby postponing the onset of neurodegenerative diseases [113].
  • Prolonged milk-induced disturbance of the insulin- IGF-1 pathway has to be considered as a possible accelerator of neurodegenerative disorders.
  • circulating IGF-I is able to cross the blood-brain barrier and enter into the brain.
  • the thymus is the only organ specialized in the establishment of immunological self-tolerance and stands at the crossroads between the immune and neuroendocrine systems [116].
  • the neuroendocrine system regulates the process of T-cell differentiation from the very early stages. T lymphocytes undergo in the thymus a complex educative process that establishes central T cell self tolerance of neuroendocrine principle. Neuroendocrine self-antigens correspond to peptide sequences that have been highly conserved throughout the evolution of one given family [116].
  • IGF-2 thymic cortex and thymic "nurse” cells
  • IGF-I thymic macrophages
  • insulin medulla
  • the blockade of thymic IGF-mediated signaling at the level of IGF ligands or IGFRs interferes with the early stages of T cell differentiation in fetal thymic organ cultures [117].
  • IGF-I stimulates thymus growth and T cell proliferation and development.
  • Thymocytes pre-T cells express IGFRl and IGFR2.
  • IGF-mediated signaling between stromal cells (thymic epithelial cells, macrophages) and immature T cells during their differentiation in the thymus [117].
  • stromal cells thymic epithelial cells, macrophages
  • IGF-I activates the PI3K-pathway, involved in the activation of cell proliferation and inhibition of apoptosis [1, 82]. Consumption of boiled farm milk during pregnancy was positively associated with increased immunoglobulin E serum levels to cow ' s milk and other food allergens [118].
  • the milk-induced maternal increase of the insulin-IGF-1 signaling might shift the insulin-IGF-1 axis in the fetal thymus, thereby damaging proper apoptosis of allergy- and autoimmune-prone T-cells explaining the co-appearance of atopic and autoimmune diseases later in life.
  • breast-fed humans have significantly lower serum IGF-I levels than those fed on a cow milk based formula [40].
  • the consumption of milk and milk products in pregnancy would be a good explanation for the dominating maternal effect in the transmission of atopic diseases.
  • Growth hormone (somatropin, GH) is a peptide hormone that stimulates growth and cell reproduction. Growth Hormone induces the release of IGF-I and insulin. By its action, growth hormone induces insulin resistance. Therefore, it is suspected to be involved in the dysregulation of insulin and IGF-I during consumption of milk.
  • Ghrelin is a 28 amino acid peptide wherein the Ser-3 residue is n-octanoylated (Nature 402 (1999) 656-660). Ghrelin is predominantly produced in the human stomach. In the anterior pituitary somatotroph cells, ghrelin binds to GH secretagogue receptor, called GHS receptor type Ia. In this acylated form, ghrelin stimulates the secretion of GH. The deacylated peptide is inactive. Octanoyl is only one possible side chain. GH induces insulin resistance in humans and mammals for physiologic growth. Ghrelin has recently been detected in human breast milk, cow milk and goat milk (Aydin S et al.
  • Ghrelin is present in human colostrums, transitional and mature milk. Peptides 27 2006; 878-882).
  • the bovine GHRL gene has recently been characterized (Colinet F et al. Molecular characterization of bovine GHRL gene. Archiv Tierzucht 2009; 52:79-84).
  • Bovine ghrelin is a peptide of 27 amino acids. During peak of lactation, plasma concentrations of bovine ghrelin and GHare greater in samples from high genetic merit Holstein-Friesian cows (Roche JR et al. Short communication : genetic selection for milk production increases plasma ghrelin in dairy cows. J Dairy Sci 2006; 89: 3471-3475).
  • bovine ghrelin determines the level of ghrelin in cow milk.
  • Bovine ghrelin has been detected recently in cow milk (Karatas F et al. Ghrelin and orotic acid increased in subclinical mastitis. Arch Physiol Biochem 2008; 114: 178-182).
  • Formula fed infants had higher serum ghrelin levels (2654.86 versus 2132.96 pg/ml) and higher IGF-I levels (3.73 versus 3.15 ng/ml) in comparison to breast-fed infants (Savino F et al. Ghrelin, leptin and IGF-I levels in breast-fed and formula fed infants in the first years of life.
  • bovine ghrelin is suspected to be the cause of increased human ghrelin levels which increase human pituitary GHsecretion and thus induce insulin resistance with hyperinsulinemia and increased IGF-I serum levels, unwanted adverse effects on human health.
  • Bovine betacellulin is found in substantial amounts in cow milk (1 930 ng/liter) and is quite stable and survives the pasteurization process and is even found in high concentrations in cheese. BTC passes the gut barrier and enters the systemic circulation to promote growth and most likely increases insulin secretion and beta-cell hyperplasia of pancreatic islet cells.
  • Betacellulin a member of the epidermal growth factor (EGF) family, was purified from the conditioned medium of a cell line derived from mouse pancreatic beta cell tumors. Its primary translational product is composed of 178 amino acid residues, which contains a signal sequence, transmembrane and cytoplasmic domains in addition to the EGF-like domain.
  • Mature betacellulin is composed of 80 amino acid residues with extensive glycosylation and has a molecular weight of about 32 kDa. Betacellulin expresses in alpha, beta, and duct cells in normal adult pancreas, and converts rat pancreatic amylase-secreting cells (AR42J cells) to insulin expressing cells together with activin. In addition, PDX-I, one of the transcriptional factors for beta cells, induces insulin gene expression in a TCl cells in the presence of Betacellulin.
  • Betacellulin also has the potential for the growth of a rat insulinoma cell line, INS-I cells, and the recombinant human betacellulin accelerates the improvement of glucose tolerance in mice with diabetes induced by selective alloxan perfusion. According to these observations, Betacellulin is thought to be necessary for differentiation and/or growth of the pancreatic beta cells.
  • betacellulin binds to Erbl and Erb4-receptor homodimers and all Erb receptor heterodimers and thus is an important nutritional stimulus of Erb- dependent carcinoma cells.
  • Alpha-lactalbumin The key element
  • Alpha-lactalbumin is an important whey protein in cow's milk ( ⁇ 1 g/l), and is also present in the milk of many other mammalian species. In primates, alpha-lactalbumin expression is upregulated in response to the hormone prolactin and increases the production of lactose. Alpha-lactalbumin forms the regulatory subunit of the lactose synthase (LS) heterodimer and ⁇ -1,4- galactosyltransferase (beta4Gal-Tl) forms the catalytic component. Together, these proteins enable LS to produce lactose by transferring galactose moieties to glucose.
  • LS lactose synthase
  • beta4Gal-Tl ⁇ -1,4- galactosyltransferase
  • alpha-lactalbumin strongly binds calcium and zinc ions and may possess bactericidal or antitumor activity.
  • a folding variant of alpha-lactalbumin, called HAMLET likely induces apoptosis in tumor and immature cells.
  • alpha-lactalbumin When formed into a complex with GaI-Tl, a galactosyltransferase, alpha-lactalbumin enhances the enzyme's affinity for glucose by about 1000 times, and inhibits the ability to polymerize multiple galactose units. This gives rise to a pathway for forming lactose by converting GaI-TI to lactose synthase.
  • the molecular weight is 14178 Da, and the isoelectric point is between 4.2 and 4.5.
  • beta-lactoglobulin does not have any free thiol group that can serve as the starting point for a covalent aggregation reaction. As a result, pure alpha-lactalbumin will not form gels upon denaturation and acidification.
  • Alpha-lactalbumin is hydrolyzed in the intestine and induces the synthesis of glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) in K-cells. This incretrin upregulates insulin synthesis in the pancreatic beta-cells.
  • GIP glucose-dependent insulinotropic polypeptide
  • Progesterone in milk fat co-inductor of insulin resistance
  • Steroid hormones are known to cross the blood-milk barrier. This effect has been recurred to for the diagnosis of the pregnancy of cows by analyzing the progesterone content of their milk (Fritsche S, Steinhart H. Occurrence of hormonally active compounds in food : a review. Eur. Food Res. Technol. 1999; 209: 153-179). Since the steroid hormone progesterone is distributed in the lipid phase, the concentration of progesterone in dairy products depends on their fat content.
  • progesterone concentrations are found to be 1.4 ⁇ g/l in low-fat milk, 10 ⁇ g/l in whole milk, 44.2 mg/kg in Gouda, 41.8-72.7 ⁇ g/kg in cream and up to 300 ⁇ g/kg in butter (Fritsche S, Steinhart H. Occurrence of hormonally active compounds in food : a review. Eur. Food Res. Technol. 1999; 209: 153-179).
  • progesterone continues to be accumulated in the tissue in perpetually pregnant dairy cows of Western dairy farming and passes into the milk, an unphysiologically increased progesterone content of milk as compared to former times is to be assumed from the "industrialized technology of milk recuperation". This could be another unrecognized risk factor of Western life style.
  • the high progesterone content of these products allows for a possible daily progesterone intake of from 40 to 50 ⁇ g, which reaches the dose range of the progestogen fraction of an ethical oral contraceptive.
  • the extremely resistant progesterone of the lipid phase of dairy products adds to the load from steroid hormones.
  • the daily uptake of bovine progesterone must be seen in an overall consideration with the uptake of progestogen-containing oral contraceptives, since the progestogenic effects of nutritive and iatrogenic progestogens are additive.
  • PCOS patients represent a special risk group, being disposed to developing diabetes mellitus, cardiovascular diseases and cancer (F ⁇ rstenberger G, Senn H-J. Insulin-like growth factors and cancer. Lancet 2002; 3: 298-302; Druckmann R, Rohr UD. IGF-I in gynaecology and obstetrics: update 2002. Maturitas 2002; 41 (Suppl 1) : S65-S83). Not only increased insulin and IGF-I serum levels are to be expected therefrom, but also a progesterone-induced increase of the autocrine production of GH in peripheral tissues.
  • progesterone increases the peripheral concentration of GH , which stimulates the local and systemic IGF-I secretion (Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel : a randomized trial. Contraception 2009; 79: 111-116).
  • This observation illustrates that a molecular cross-talk between the GH/IGF-1 axis and steroid hormones, such as progesterone, exists in mammals (Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel : a randomized trial. Contraception 2009; 79: 111-116).
  • Lactogens placental lactogen and/or prolactin induce this up-regulation and remain elevated throughout gestation [116b]. There is no doubt that prolactin is a most important inducer of postnatal beta-cell proliferation (postnatal beta- cell burst) and insulin secretion.
  • colostrum of various species including human and bovine colostrum (500-800 ng/ml) contains very high amounts of prolactin.
  • Cow milk contains high levels of bovine prolactin (6-8 ng/ml) [3].
  • Human prolactin compared to bovine prolactin exhibits 73.1% protein identity and 80.3% DNA identity.
  • Prolactin is known to be absorbed in the intestine during the postnatal period.
  • continuous cow milk consumption in infancy and adulthood may result in increased intestinal prolactin absorption, especially in conditions with disturbed intestinal permeability barrier.
  • Alpha-lactalbumin is a unique protein of milk which contains high amounts of tryptophane, the precursor of serotonin (5- hydroxytryptamine) which stimulates the secretion of pituitary GH and prolactin (Markus CR. Dietary amino acids and brain serotonin function; implications for stress-related affective changes. Neuromol Med 2008; 10: 247).
  • milk and especially whey proteins containing alpha-lactalbumin will increase postprandial prolactin and GH levels which exert adverse mitogenic effects on pancreatic beta-cells (promotion of type 2 diabetes mellitus), on adipocytes (promotion of obesity) and other somatic cells like cancer cells (promotion of cancer).
  • Cow milk and cow milk protein consumption with its high insulin and IGF-I stimulatory effects has to be regarded as a violation of a physiological principal in mammalian nutrition developed during the eons of mammalian evolution.
  • the short-sighted view on the beneficial effects of milk consumption on bone formation and bone mineralization ignores already well documented facts of harmful disease- and cancer promoting effects of milk protein consumption.
  • This scientific principle can be applied to insulin/IGF-1 signaling in various cell systems. According to the presented hypothesis cow milk consumption has to be regarded as a health hazard for humans which afford immediate intervention.
  • the object of the present invention to overcome the drawbacks of prior art, especially by reduction of the insulinotropic effects of milk.
  • the solution to the health hazards of milk is the modification/attenuation of milk ' s insulinotropic and mitogenic properties.
  • a measure of the insulinotropic effect of milk is the insulinemic index of milk.
  • the insulinemic index of milk ranges between 90-148 [Ostman EM, LiIj berg Elmstahl HGM et al. : Inconsistency between glycemic and insulinemic reponses to regular and fermented milk products. Am J Clin Nutr 2001; 74:96- 100; Hoyt G, Hickey MS, Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr 2005; 93: 175- 177; Holt S, Brand Miller J, Petocz P. An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods.
  • Major contributors to milk ' s high insulinemic index are the GIP secretion induced by whey proteins, especially alpha-lactalbumin, the growth factors of the whey protein fraction, especially bovine prolactin and betacellulin and the IGF-I which is transported in the casein fraction of milk.
  • the method of the invention comprises the reduction of the content or activity of at least one of alpha-lactalbumin, ghrelin, betacellulin or prolactin.
  • the major focus of the invention is the reduction of alpha- lactalbumin as a most important precursor for pituitary GH and prolactin secretion as well as intestinal incretin formation (GIP, GLP-I and cholecystokinin)
  • the method of the invention is also a method of treating milk to reduce the ability of milk to induce GH and prolactin in a human being upon consumption.
  • a further embodiment is a method of treating casein to reduce the ability of casein to induce IGF-I in a human being upon consumption together with treating whey proteins to reduce the ability of whey proteins to induce insulin in a human being upon consumption.
  • milk is adjusted to have an insulinemic index between 40 and 80.
  • the insulinemic index is defined according to Holt S, Brand Miller J, Petocz P.
  • An insulin index of foods the insulin demand generated by 1000-kJ portions of common foods. Am J Clin Nutr 1997; 66: 1264-1276]
  • the insulinemic index is in the range of 40 to 50.
  • the process comprises the step of a hydrolytic treatment.
  • the hydrolytic treatment is conducted until the ability of casein to induce IGF-I and/or the ability of whey proteins to induce insulin and/or the ability of milk to induce growth hormone and/or the content or activity of ghrelin or betacellulin or alpha-lactalbumin is reduced.
  • the hydrolytic treatment can be conducted using one or more proteases, preferably from microorganisms, bacteria or fungi.
  • One very preferred treatment is directed against content or activity of ghrelin and/or betacellulin.
  • the treatment either comprises a hydrolytic treatment to hydrolyze the peptide structure of ghrelin and/or betacellulin.
  • a further possibility to reduce the activity of bovine ghrelin would be the addition of an anti-ghrelin Spiegelmer (Kobelt P et al. Anti-ghrelin Spiegelmer NOX-BI l inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut 2006; 55:788-792; Shearman LP et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006; 147: 1517-1526). This would also work with betacellulin Spiegelmer.
  • a further possibility is the specific inactivation of ghrelin by hydrolyses of the acyl group on Ser-3.
  • a further possibility is the removal of ghrelin and/or betacellulin by absorption, especially immunoabsorption.
  • Filtration can for example be used to separate soluble whey proteins from casein proteins which have a higher molecular weight.
  • Absorptive material may be used to bind materials from the milk, especially when used in form of an affinity treatment.
  • affinity adsorption is suitable.
  • galactose or galactosyltransferase are useful. They could be coated on beads, surfaces or the like.
  • alpha-lactalbumin is denatured by high-pressure treatment as described in Huppertz T, Fox PF, de Kruif KG, Kelly AL. High- pressure induce changes in bovine milk proteins: a review. Biochim Biophys Acta 2006; 1764: 593-598.
  • a method to increase the content of alpha-lactalbumin is described in Kiesner C et al. (2000) Manufacturing of ⁇ -lactalbumin-enriched whey systems by selective thermal treatment in combination with membrane processes. Lait 80: 99-111. In a modified way, this method can also be used to reduce the content of alpha-lactalbumin.
  • prolactin affinity binding procedures For the removal of prolactin affinity binding procedures are applied. Biotechnologically produced prolactin binding proteins are fixed to adsorber systems or beads to remove free prolactin and bovine lactogen of milk.
  • a further embodiment of the invention additionally comprises a step to reduce bovine IGF-I in milk.
  • a person skilled in the art is able to modify the milk to adjust the respective levels of insulinotropic factors in a way that milk or milk- derived products, especially the alpha-lactalbumin amount of the whey protein fraction for the production of infant formula will exhibit an insulinemic index in the comparable range of the insulinemic index of human breast milk.
  • the produced future whey fraction will be adjusted in a way that infant formula feeding to a human newborn will exert postprandial insulin, glucose-dependent insulinotropic polypeptide and IGF-I responses comparable to the postprandial and long-term responses of physiologic breast-feeding.
  • a further embodiment of the invention is milk or a product from milk wherein the milk has been treated according to the process of the invention.
  • a further embodiment is a milk or a product from milk, wherein
  • casein is modified to reduce the ability of casein to induce IGF-I in a human being upon consumption
  • - whey proteins are modified to reduce the ability of whey proteins to induce insulin in a human being upon consumption or
  • - milk is modified to reduce the ability of milk to induce growth hormone in a human being upon consumption or - milk is modified to reduce the content or activity of alpha-lactalbumin
  • - milk is modified to reduce the content or activity of ghrelin or
  • - milk is modified to reduce the content or activity of prolactin.
  • the whey protein fraction is preferentially modified especially alpha-lactalbumin.
  • casein to reduce the ability of casein to induce IGF-I in a human being upon consumption of the milk and/or
  • the whole growth hormone containing basic whey fraction (with IGF-I, IGF-I, PDGF, FGF, TGFbeta, betacellulin, prolactin and alpha-lactalbumin) is removed from pasteurized raw milk.
  • IGF-I, IGF-I, PDGF, FGF, TGFbeta, betacellulin, prolactin and alpha-lactalbumin is removed from pasteurized raw milk.
  • One possible method follows the technique of LACTERMIN production by ultrafiltration and column chromatography described in Dyer et al. Food and Chemical Toxicology 46 (2008), 1659-1665. The combination of ion exchange chromatography and micro- and ultrafiltration of milk is appropriate.
  • the use of the treated milk of the invention is especially useful for the preparation of milk products, especially in the field of baby food and infant formula.
  • the milk of the invention is further useful for the preparation of a product for the treatment or prevention of disease selected from diabetes type II and obesity.
  • the milk of the invention with reduced insulinemic index is useful for adolescents to prevent and treat acne and other hyperproliferative diseases like psoriasis.
  • Figure 1 shows IGF-I, IGF-2 and insulin signal transduction and receptor cross-reactivity
  • Figure 2 shows insulinotropic and IGF-I inducing effect of milk protein and milk protein fractions
  • Figure 3 shows synopsis of milk and milk protein induced disturbances of insulin/IGF-1 signaling from fetal life to senescence and associated chronic diseases of Westernized societies.
  • ACTH adrenocorticotropic hormone
  • AGA appropriate for gestational age
  • IGF insulin-like growth factor
  • IGFBP IGF binding protein
  • IGFlR IGF-I receptor
  • IGF2R IGF- 2 receptor
  • MAPK mitogen activated protein kinase
  • PCOS polycystic ovary syndrome
  • PI3K phosphoinositide-3-kinase
  • SREBP sterol response element binding protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Pediatric Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet un procédé permettant de traiter du lait, des produits lactés ou une formulation pour bébés à base de lait pour obtenir du lait, comprenant au moins l'une des étapes consistant : a) à traiter le lait pour réduire la teneur ou l'activité de l'alpha-lactalbumine ou; b) à traiter la caséine pour réduire la capacité de la caséine à induire l'IGF-1 chez un être humain qui en consomme et à traiter les protéines de lactosérum pour réduire la capacité des protéines de lactosérum à induire l'insuline chez un être humain qui en consomme; c) à traiter le lait pour réduire la capacité du lait à induire l'hormone de croissance chez un être humain qui en consomme; d) à traiter le lait pour réduire la teneur ou l'activité de la prolactine; e) à traiter le lait pour réduire la teneur ou l'activité de la bêtacelluline; f) à traiter le lait pour réduire la teneur ou l'activité de la ghréline, un indice insulinémique du lait étant de préférence modifié de sorte à être compris dans la gamme allant de 40 à 80. Les produits lactés sont moins insulinotropes, moins mitogènes en comparaison avec le lait et les produits lactés non traités.
PCT/EP2010/054937 2009-04-15 2010-04-15 Lait et produits lactés modifiés pour présenter un indice insulinémique réduit et/ou une activité mitogène réduite Ceased WO2010119088A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP09157997.9 2009-04-15
EP09157997 2009-04-15
EP09174910.1 2009-11-03
EP09174910 2009-11-03
EP10154973.1 2010-02-27
EP10154973 2010-02-27
EP10156858 2010-03-18
EP10156858.2 2010-03-18

Publications (2)

Publication Number Publication Date
WO2010119088A2 true WO2010119088A2 (fr) 2010-10-21
WO2010119088A3 WO2010119088A3 (fr) 2011-06-30

Family

ID=42982925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/054937 Ceased WO2010119088A2 (fr) 2009-04-15 2010-04-15 Lait et produits lactés modifiés pour présenter un indice insulinémique réduit et/ou une activité mitogène réduite

Country Status (1)

Country Link
WO (1) WO2010119088A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078974A1 (fr) * 2013-11-29 2015-06-04 Nestec S.A. Nutriment pour nourrisson pour améliorer la sensibilité à l'insuline au cours de la vie future

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2319186A (en) * 1939-03-16 1943-05-11 Ind Patents Corp Milk product
US2822277A (en) * 1956-02-09 1958-02-04 Carnation Co Process for manufacturing an evaporated food product and the product produced thereby
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
WO1993004171A1 (fr) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Beta-caseine humaine, procede de preparation et utilisation
DK8892D0 (da) * 1992-01-23 1992-01-23 Symbicom Ab Humant proteingen
GB9314802D0 (en) * 1993-07-16 1993-08-25 Pharmaceutical Proteins Ltd Modified proteins
JPH10502816A (ja) * 1994-07-13 1998-03-17 ピーピーエル・セラピューティクス（スコットランド）リミテッド α−ラクトアルブミン遺伝子構造物
WO1996040203A1 (fr) * 1995-06-07 1996-12-19 Ohio University/Edison Biotechnology Institute Methodes de traitement utilisant des antagonistes de l'hormone de croissance
IT1277964B1 (it) * 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
EP1573033A4 (fr) * 2002-05-24 2009-03-04 A2 Corp Ltd Methode de genotypage d'animaux
JP2006515512A (ja) * 2002-10-02 2006-06-01 ノボザイムス アクティーゼルスカブ プロテアーゼ処理により改良された乳およびその製造法
WO2006069918A1 (fr) * 2004-12-27 2006-07-06 Nestec S.A. Utilisation d’une preparation pour nourrissons a teneur proteique reduite
AU2006266546B2 (en) * 2005-07-01 2012-01-12 N.V. Nutricia Infant nutrition with hydrolised proteins
WO2008054192A1 (fr) * 2006-11-02 2008-05-08 N.V. Nutricia Utilisation de compositions alimentaires pour éviter des maladies
PT1962823E (pt) * 2005-12-23 2015-06-29 Nutricia Nv Composição de ácidos gordos polinsaturados compreendendo, proteínas de manganês e/ou molibdénio para melhorar a composição de membrana
FR2900342B1 (fr) * 2006-04-27 2010-08-20 Cie Laitiere Europeenne Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie
EP2133090A4 (fr) * 2007-03-12 2012-02-01 Megmilk Snow Brand Co Ltd Stimulateur de sécrétion d'hormone de croissance
WO2009101199A2 (fr) * 2008-02-15 2009-08-20 Bodo Melnik Traitement de l'acné vulgaire, de la rosacée et du rhinophyme
US20120058190A1 (en) * 2009-02-17 2012-03-08 Technion-Research & Development Foundation Ltd Food containing prolactin

Non-Patent Citations (163)

* Cited by examiner, † Cited by third party
Title
"Beneficial effects of lipids and prolactin on insulin secretion and P-cell proliferation: a role for lipids in the adaptation of islets to pregnancy", J ENDOCRINOL, vol. 197, 2008, pages 265 - 276
"Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial", CONTRACEPTION, vol. 79, 2009, pages 111 - 116
ADEBAMOWO CA; SPIEGELMAN D; BERKEY CS; DANBY FW; ROCKETT HH; COLDITZ GA ET AL.: "Milk consumption and acne in adolescent girls", DERMATOLOGY ONLINE J, vol. 12, 2006, pages 1 - 12
ADEBAMOWO CA; SPIEGELMAN D; BERKEY CS; DANBY FW; ROCKETT HH; COLDITZ GA ET AL.: "Milk consumption and acne in teenaged boys", J AM ACAD DERMATOL, vol. 58, 2008, pages 787 - 793
AILHAUD G; GRIMALDI P; NEGREL R.: "A molecular view of adipose tissue", INT J OBES, vol. 16, no. 2, 1992, pages S17 - S21
AIZAWA H; NIIMURA M.: "Elevated serum insulin-like growth factor-1 (IGF-1) levels in women with postadolescent acne", J DERMATOL, vol. 22, 1995, pages 249 - 252
AKCAKUS M; KOKLU E; KURTOGLU S; KULA M; KOKLU SS.: "The relationship among intrauterine growth, insulin-like growth factor I (IGF-I), IGF-binding protein-3, and bone mineral status in newborn infants", AM J PERINATOL, vol. 23, 2006, pages 473 - 480
AMADUCCI L; TESCO G.: "Aging as a major risk for degenerative diseases of the central nervous system", CURR OPIN NEUROL, vol. 7, 1994, pages 283 - 286
ANDRONICO G; MANGANO MT; FERRARA L; LAMANNA D; MULE G; CERASOLA G.: "Insulin-like growth factor 1 and pressure load in hypertensive patients", AM J HYPERTENS, vol. 9, 1996, pages 607 - 609
ATTIA N; TAMBORLANE WV; HEPTULLA R; MAGGS D; GROZMAN A; SHERWIN RS ET AL.: "The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity", J CLIN ENDOCRINOL METAB, vol. 83, 1998, pages 1467 - 1471
AYDIN S ET AL.: "Ghrelin is present in human colostrums, transitional and mature milk", PEPTIDES, vol. 27, 2006, pages 878 - 882
BAGEMAN E; INGVAR C; ROSE C; JERNSTROM H.: "Absence of the common insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women", BR J CANCER, vol. 96, 2007, pages 712 - 717
BAQUEDANO MS; BERENSZTEIN E; SARACO N; DORN GV; DE DAVILA MT; RIVAROLA MA ET AL.: "Expression of the IGF system in human adrenal tissues from early infancy to late puberty: implications for the development of adrenarche", PEDIAT RES, vol. 58, 2005, pages 451 - 458
BELGOROSKY A; BAQUEDANO MS; GUERICO G; RIVAROLA MA.: "Adrenarche: postnatal adrenal zonation and hormonal and metabolic regulation", HORM RES, vol. 70, 2008, pages 257 - 267
BEN-JONATHAN N; LA PENSEE CR; LA PENSEE EW.: "What can we lerarn from rodents about prolactin in humans?", ENDOCR REV, vol. 29, 2008, pages 1 - 41
BERENSZTEIN EB; BAQUEDANO MS; PEPE CM; COSTANZO M; SARACO NI; PONZIO R ET AL.: "Role of IGFs and insulin in the human testis during postnatal activation: differentiation of steroidogenic cells", PEDIATR RES, vol. 63, 2008, pages 662 - 666
BERKER B; EMRAL R; DEMIREL C; CORAPCIOGLU D; UNLU C; KOSE K.: "Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy", GYNECOL ENDOCRINOL, vol. 19, 2004, pages 125 - 133
BLÜHER S; KRATZSCH J; KIESS W.: "Insulin-like growth factor I, growth hormone and insulin in white adipose tissue", BEST PRACT RES CLIN ENDOCRINOL METAB, vol. 19, 2005, pages 577 - 587
BLUM JW; BAUMRUCKER CR.: "Bioactive Components of Milk. Advances in Experimental Medicine and Biology", vol. 606, 2008, SPRINGER, article "Insulin-like growth factors (IGFs), IGF binding proteins, and other endocrine factors in milk: role in the newborn", pages: 397 - 422
BOYD DB.: "Insulin and cancer", INTEGR CANCER THER, vol. 2, 2003, pages 315 - 329
BRINK M; CHRAST J; PRICE SR; MITCH WE; DELAFONTAINE D.: "Angiotensin II stimulatesd gene expression of cardiac insulin-like growth factor I and its receptor through effects on blood pressure and food intake", HYPERTENSION, vol. 34, 1999, pages 1053 - 1059
BRISMAR K; FERNQVIST-FORBES E; WAHREN J; HALL K.: "Effect of insulin on the hepatic production of insulin-like growth factor binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes", J CLIN ENDOCRINOL METAB, vol. 79, 1994, pages 872 - 878
BRUBAKER PL; ANINI Y.: "Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2", CAN J PHYSIOL PHARMACOL, vol. 81, 2003, pages 1005 - 1012
BYRNE C; COLDITZ GA; WILLETT WC; SPEIZER FE; POLLAK M; HANKINSON SE.: "Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density", CANCER RES, vol. 60, 2000, pages 3744 - 3748
CADOGAN J; EASTELL R; JONES N; BARKER ME.: "Milk intake and bone mineral acquisition in adolescent girls. A randomised, controlled intervention trial", BR MED J, vol. 315, 1997, pages 1255 - 1260
CAGNACCI A; FERRARI S; TIRELLI A; ZANIN R; VOLPE A.: "Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial", CONTRACEPTION, vol. 79, 2009, pages 111 - 116
CAGNACCI A; FERRARI S; TIRELLI A; ZANIN R; VOLPE A: "Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial", CONTRACEPTION, vol. 79, 2009, pages 111 - 116
CAPPEL M; MAUGER D; THIBOUTOT D.: "Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women", ARCH DERMATOL, vol. 141, 2005, pages 333 - 338
CARA JF; ROSENFIELD RL; FURLANETTO RW.: "A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt", AM J DIS CHILD, vol. 141, 1987, pages 562 - 564
CHAN JM; STAMPFER MJ; GIOVANNUCCI E; GANN PH; MA J; WILKINSON P ET AL.: "Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study", SCIENCE, vol. 279, 1998, pages 563 - 566
CHENG I; STRAM DO; PENNEY KL; PIKE M; LE MARCHAND L; KOLONEL LN ET AL.: "Common genetic variation in IGF1 and prostate cancer risk in the Muliethnic Cohort", J NAT CANCER INST, vol. 98, 2006, pages 123 - 134
CHIESA C; OSBORN JF; HAASS C ET AL.: "Ghrelin, leptin, IGF-1, IGFBP-3, and insulin concentrations at birth: Is there a relationship with fetal growth and neonatal anthropometry?", CLIN CHEM, vol. 54, 2008, pages 550 - 558
CLEMMONS DR.: "Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer", NATURE, vol. 6, 2007, pages 821 - 833
COHEN E; DILLIN A.: "The insulin paradox: aging, proteotoxicity and neurodegeneration", NATURE REV NEUROSCIENCE, vol. 9, 2008, pages 759 - 767
COLINET F ET AL.: "Molecular characterization of bovine GHRL gene", ARCHIV TIERZUCHT, vol. 52, 2009, pages 79 - 84
COLLIER RJ; MILLER MA; HILDEBRANDT JR; TORKELSON AR; WHITE TC; MADSEN KS ET AL.: "Factors affecting insulin-like growth factor-I concentration in bovine milk", J DAIRY SCI, vol. 74, 1991, pages 2905 - 2911
COLLIER RJ; MILLER MA; MCLAUGHLIN CL; JOHNSON HD; BAILE CA.: "Effects of recombinant somatotopin (rbST) and season on plasma and milk insulin-like growth factors I (IGF-I) and II (IGF-II) in lactating dairy cows", DOMESTIC ANIMAL ENDOCRINOL, vol. 35, 2008, pages 16 - 23
CORDAIN L; LINDEBERG S; HURTADO M; HILL K; EATON SB; BRAND-MILLER J.: "Acne vulgaris. A disease of Western civilization", ARCH DERMATOL, vol. 138, 2002, pages 1584 - 1590
CROWE FL; KEY TJ; ALLEN NE ET AL.: "The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 18, 2009, pages 1333 - 1340
DENLEY A; COSGROVE LJ; BOOKER GW; WALLACE JC; FORBES BE.: "Molecular interactions of the IGF system", CYTOKINE & GROWTH FACTOR REV, vol. 16, 2005, pages 421 - 439
DENLEY A; WALLACE JC; COSGROVE LJ; FORBES BE.: "The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review", HORM METAB RES, vol. 35, 2003, pages 778 - 785
DEPLEWSKI D; ROSENFIELD RL.: "Role of hormones in the pilosebaceous unit development", ENDOCRINE REV, vol. 21, 2000, pages 263 - 392
DIAMOND MP; SIMONSON DC; DE FRONZO RA.: "Menstrual cyclicity has a profound effect on glucose homeostasis", FERTIL STERIL, vol. 52, 1989, pages 204 - 208
DIORIO C; POLLAK M; BYRNE C; MASSE B; HEBERT-CROTEAU N; YAFFE M ET AL.: "Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 14, 2005, pages 1065 - 1073
DRUCKMANN R; ROHR UD., MATURITAS, vol. 41, no. 1, 2002, pages S65 - S83
DRUCKMANN R; ROHR UD.: "IGF-1 in gynaecology and obstetrics", MATURITAS, vol. 41, no. 1, 2002, pages S65 - S83
DU J; PENG T; SCHEIDEGGER KJ; DELAFONTAINE P.: "Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox sensitive mechanism", ARTERIOSCLER THROMB VASC BIOL, vol. 19, 1999, pages 2119 - 2126
DU J; PENG T; SCHEIDEGGER KJ; DELAFONTAINE P.: "Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism", ARTERIOSCLER THROMB VASC BIOL, vol. 19, 1999, pages 2119 - 2126
DYER ET AL., FOOD AND CHEMICAL TOXICOLOGY, vol. 46, 2008, pages 1659 - 1665
EGE MJ; HERZUM I; BÜCHELE G; KRAUSSS-ETSCHMANN S; LAUENER RP; ROPONEN M ET AL.: "Prenatal exposure to a farm environment modifies atopic sensitization at birth", J ALLERGY CLIN IMMUNOL, vol. 122, 2008, pages 407 - 412
ESSAGHIR A; DIF N; MARBEHANT CY; COFFER PJ ET AL.: "The transcription of FOXO genes is stimulated by FOX03 and repressed by growth factors", J BIOL CHEM, vol. 284, 2009, pages 10334 - 10342
ESTERLE L; SABATIER J-P; METZ FG; WALRANT-DEBRAY 0; GUAYDIER-SOUQUIERES G; JEHAN F ET AL.: "Milk, rather than other foods, is associated with vertebral bone mass and circulating IGF-1 in female adolescents", OSTEOPOROS INT, 2008
FALORNI A; BINI V; CABIATI G; PAPI F; ARZANO S; CELI F ET AL.: "Serum levels of type I procollagen C-terminal peptide, insulin-like growth factor-I (IGF-I), and IGF binding protein-3 in obese children and adolescents: relationship to gender, pubertal development, growth, insulin, and nutritional status", METABOLISM, vol. 46, 1997, pages 862 - 871
FORSTENBERGER G; SENN H-J.: "Insulin-like growth factors and cancer", LANCET, vol. 3, 2002, pages 298 - 302
FOWDEN AL; FORHEAD AJ.: "Endocrine mechanisms of intrauterine programming", REPRODUCTION, vol. 127, 2004, pages 515 - 526
FRANCIS GL; UPTON FM; BALLARD FJ; MCNEIL KA; WALLACE JC.: "Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form", BIOCHEM J, vol. 251, 1988, pages 95 - 103
FRITSCHE S; STEINHART H.: "Occurrence of hormonally active compounds in food: a review", EUR. FOOD RES. TECHNOL., vol. 209, 1999, pages 153 - 179
FRITSCHE S; STEINHART H: "Occurrence of hormonally active compounds in food: a review", EUR. FOOD RES. TECHNOL., vol. 209, 1999, pages 153 - 179
FÜRSTENBERGER G; SENN H-J: "Insulin-like growth factors and cancer", LANCET, vol. 3, 2002, pages 298 - 302
GAARD M; TRETLI S; LOKEN EB.: "Dietary fat and the risk of breast cancer: a prospective study of 25,892 Norwegian women", INT J CANCER, vol. 63, 1995, pages 13 - 17
GANNON MC; NUTTAL FQ; KREZOWSKI PA; BILLINGTON CJ; PARKER S.: "The serum insulin and plasma glucose responses to milk and fruit in type 2 (non- insulin-dependent) diabetic patients", DIABETOLOGICA, vol. 29, 1986, pages 784 - 791
GAO X; LAVALLEY M; TUCKER KL.: "Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis", J NATL CANCER INST, vol. 97, 2005, pages 1768 - 1777
GEENEN V.: "Thymus-dependent T cell tolerance of neuroendocrine functions. Principles, reflections, and implications for tolerogenic/negative self-vaccination", ANN NY ACAD SCI, vol. 1088, 2006, pages 284 - 296
GICQUEL C; LE BOUC Y.: "Hormonal regulation of fetal growth", HORM RES, vol. 65, no. 3, 2006, pages 28 - 33
GIOVANNUCCI E; POLLAK M; LIU Y; PLATZ EA; MAJEED N; RIMM EB ET AL.: "Nutritional predictors of insulin-like growth factor I and their relationships to cancer in man", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 12, 2003, pages 84 - 89
GODSLAND IF; WALTON C; FELTON C; PROUDLER A; PATEL A; WYNN V.: "Insulin resistance, secretion, and metabolism in users of oral contraceptives", J CLIN ENDOCRINOL METAB, vol. 74, 1991, pages 64 - 70
GUERCIO G; RIVAROLA MA; CHALER E; MACEIRAS M; BELGOROSKY A.: "Relationship between the growth hormone/insulin-like growth factor-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal girls", J CLIN ENDOCR METAB, vol. 88, 2003, pages 1389 - 1393
HALES CN; BARKER DJ.: "The thrifty phenotype hypothesis", BR MED BULL, vol. 60, 2001, pages 5 - 20
HALL WL ET AL.: "Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite", BR J NUTR, vol. 89, 2003, pages 239
HAUNER H; WABITSCH M; ZWIAUER K; WIDHALM K; PFEIFFER EF.: "Adipogenic activity in sera from obese children before and after weight reduction", AM J CLIN NUTR, vol. 50, 1989, pages 63 - 67
HEANEY RP; MCCARRON DA; DAWSON-HUGHES B; OPARIL S; BERGA SL; STERN JS ET AL.: "Dietary changes favorably affect bone remodeling in older adults", J AM DIET ASSOC, vol. 99, 1999, pages 1228 - 1233
HENNINGSON M; BAGEMAN E; SANDBERG T; BORG A; OLLSON H; JERNSTROM H.: "Absence of the common IGF1 19CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families", FAM CANCER, vol. 6, 2007, pages 455 - 452
HOLMES MD; POLLAK MN; WILLETT WC; HANKINSON SE.: "Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 11, 2002, pages 852 - 861
HOLT S; BRAND MILLER J; PETOCZ P.: "An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods", AM J CLIN NUTR, vol. 66, 1997, pages 1264 - 1276
HOLT S; BRAND MILLER J; PETOCZ P: "An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods", AM J CLIN NUTR, vol. 66, 1997, pages 1264 - 1276
HOPPE C; MOLGAARD C; DALUM C ET AL.: "Differential effects of casein versus whey on fasting plasma levels of insulin, IGF-1 and IGF-1/IGFBP-3: results from a randomized 7-day supplementation study in prepubertal boys", EUR J CLIN NUTR, vol. 63, 2009, pages 1076 - 1083
HOPPE C; MOLGAARD C; JUUL A; MICHAELSEN KF.: "High intakes of skimmed milk, but not meat increase serum IGF-I and IGFBP-3 in eight-year-old boys", EUR J CLIN NUTR, vol. 58, 2004, pages 1211 - 1216
HOPPE C; MOLGAARD C; JUUL A; MICHAELSEN KF.: "High intakes of slimmed milk, but not meat, increase serum IGF-I and IGFBP-3 in eight year old boys", EUR J CLIN NUTR, vol. 58, 2004, pages 1211 - 1216
HOPPE C; MOLGAARD C; MICHAELSEN KF.: "Cow's milk and linear growth in industrialized and developing countries", ANN REV NUTR, vol. 26, 2006, pages 131 - 173
HOPPE C; MOLGAARD C; VAAG A; MICHAELSEN KF.: "The effect of seven-day supplementation with milk protein fractions and milk minerals on IGFs and glucose-insulin metabolism in Danish pre-pubertal boys", DEPARTMENT OF HUMAN NUTRITION FACULTY OF LIFE SCIENCES, 2008
HOPPE C; UDAM TR; LAURITZEN L; MOLGAARD C; JUUL A; MICHAELSEN KF.: "Animal protein intake, serum insulin-like growth factor I, and growth in healthy 2.5-y-old Danish children", AM J CLIN NUTR, vol. 80, 2004, pages 447 - 452
HOYT G; HICKEY MS; CORDAIN L.: "Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk", BR J NUTR, vol. 93, 2005, pages 175 - 177
HUPPERTZ T; FOX PF; DE KRUIF KG; KELLY AL.: "High-pressure induce changes in bovine milk proteins: a review", BIOCHIM BIOPHYS ACTA, vol. 1764, 2006, pages 593 - 598
IABLOKOV V; SYDORA BC; FOSHAUG R ET AL.: "Naturally occurring glycoalkaloids in potatoes aggravate intestinal inflammation in two mouse models of inflammatory bowel disease", DIG DIS SCI, 2010
IBANEZ L; ONG K; VALLS C; MARCOS MV; DUNGER DB; DE ZEGHER F.: "Metformin treatment to prevent early puberty in girls with precocious pubarche", J CLIN ENDOCRINOL METAB, vol. 91, 2006, pages 2888 - 2891
IBANEZ L; POTAU N; FRANCOIS I; DE ZEGHER F.: "Precocious pubarche, hyperinsulinism and ovaria hyperandrogensim in girls: relation to reduced fetal growth", J CLIN ENDOCRINOL METAB, vol. 83, 1998, pages 3558 - 3662
IBANEZ L; VALLS C; POTAU N; MARCOS MV; DE ZEGHER F.: "Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birth weight effects", CLIN ENDOCRINOL, vol. 55, 2001, pages 667 - 672
IRWIN N; FLATT PR.: "Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications", DIABETOLOGIA, vol. 52, 2009, pages 1724 - 1731
ISHIZUKA B ET AL.: "Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain", J CLIN ENDOCRINOL METAB, vol. 57, 1983, pages 1111
JERNSTROM H; CHU W; VESPRINI D; TAO Y; MAJEED N; DEAL C ET AL.: "Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for pre-menopausal breast cancer risk", MOL GENET METAB, vol. 72, 2001, pages 144 - 154
JERNSTROM H; SANDBERG T; BAGEMAN; BORG A; OLSSON H.: "Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implication for risk of early-onset breast cancer in young women from hereditary breast cancer families", INT J GYNECOL CANCER, vol. 16, no. 2, 2006, pages 497
JOHANSSON M; MCKAY JD; STATTIN P; CANZIAN F; BOILLOT C; WIKLUND F ET AL.: "Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer", INT J CANCER, vol. 120, 2006, pages 539 - 542
KAPPELER L; DE MAGALHAES FILHO C; LENEUVE P ET AL.: "Early postnatal nutrition determines somatotropic function in mice", ENDOCRINOLOGY, vol. 150, 2009, pages 314 - 323
KARADAG AS; ERTUGRUL DT; TUTAL E ET AL.: "Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: does isotretinoin affect growth hormone physiology. Br J Dermatol 2010 [Epub ahead of print].64c Melnik BC. FoxOl - the key for the pathogenesis and therapy of acne?", J DTSCH DERMATOL GES, vol. 8, pages 105 - 113
KARATAS F ET AL.: "Ghrelin and orotic acid increased in subclinical mastitis", ARCH PHYSIOL BIOCHEM, vol. 114, 2008, pages 178 - 182
KECHA 0; BRILOT F; MARTENS H; FRANCHIMONT N; RENARD C; GREIMERS R ET AL.: "Involvement of insulin-like growth factors in early T-cell development: a study of using fetal thymic organ cultures", ENDOCRINOLOGY, vol. 141, 2000, pages 1209 - 1217
KHORSANDI M; FAGIN JA; FISHBEIN MC; FORRESTER JS; CERCEK B.: "Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats", ATHEROSCLEROSIS, vol. 93, 1992, pages 115 - 122
KIESNER C ET AL.: "Manufacturing of a-lactalbumin-enriched whey systems by selective thermal treatment in combination with membrane processes", LAIT, vol. 80, 2000, pages 99 - 111
KOBELT P ET AL.: "Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats", GUT, vol. 55, 2006, pages 788 - 792
KOKLU E; KURTOGLU S; AKCAKUS M; YIKILMAZ A; GUNES T.: "Serum insulin-like growth factor-I (IGF-I) IGF binding protein-3 (IGFBP-3) and leptin levels are related to abdominal aortic intima-media thickness in macrosomic newborns", GROWTH HORM IGF RES, vol. 17, 2007, pages 26 - 32
KOLETZKO B; VON KRIES R; CLOSA R ET AL.: "Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical tral", AM J CLIN NUTR, vol. 89, 2009, pages 1836 - 1845
KOLETZKO B; VON KRIES R; MONASTEROLO RC ET AL.: "Can infant feeding choices modulate later obesity risk?", AM J CLIN NUTR, vol. 89, 2009, pages 1502S - 1508S
KULLER LH.: "The etiology of breast cancer - From epidemiology to prevention", PUBLIC HEALTH REV, vol. 23, 1995, pages 157 - 213
LARNKJAER A; INGSTRUP HK; SCHACK-NIELSEN L; HOPPE C; MOLGAARD C; SKOVGAARD IM ET AL.: "Early programming of the IGF-I axis: Negative association between IGF-I in infancy and late adolescence in a 17-year longitudinal follow-up study of healthy subjects", GROWTH HORMONE & IGF RESEARCH, 2008
LE ROITH D.; INSULIN-LIKE GROWTH FACTORS, N ENGL J MED, vol. 336, 1997, pages 633 - 640
LEON DA.: "Fetal growth and adult disease", EUR J CLIN NUTR, vol. 52, no. 1, 1998, pages 72 - 78
LILJEBERG EH; BJORCK I.: "Milk as a supplement to mixed meals may elevate postprandial insulinaemia", EUR J CLIN NUTR, vol. 55, 2001, pages 994 - 999
LO H-C; TSAO L-Y; HSU W-Y; CHEN H-N; YU W-K; CHI C-Y.: "Relation of cord serum levels of growth hormone, insulin-like growth factors, insulin-like growth factor binding proteins, leptin, and interleukin-6 with birth weight, birth length, and head circumference in term and preterm neonates", NUTRITION, vol. 18, 2002, pages 604 - 608
LUCAS A; SARSON DL; BLACKBURN AM; ADRAIN TE; AYNSLEY-GREEN A; BLOOM SR.: "Breast vs bottle: endocrine responses are different with formula feeding", LANCET, vol. 1, 1980, pages 1267 - 1269
LUDWIG D.: "The glycemic index: physiological mechanisms relating to obesity, diabetes and cardiovascular disease", JAMA, vol. 287, 2002, pages 2414 - 2423
MA J; GIOVANNUCCI E; POLLAK M; CHAN JM; GAZIANO JM; WILLETT W ET AL.: "Milk- intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in man", J NATL CANCER INST, vol. 93, 2001, pages 1330 - 1336
MAJOR JM; LAUGHLIN GA; KRITZ-SILVERSTEIN D ET AL.: "Insulin-like growth factor-I and cancer mortality in older men", J CLIN ENDOCRINOL METABOL, vol. 95, pages 1054 - 1059
MANNION CA; GRAY-DONALD K; KOSKI KG.: "Association of low intake of milk and vitamin D during pregnancy with decreased birth weight", CAN MED ASSOC J, vol. 174, 2006, pages 1273 - 1277
MARKUS CR.: "Dietary amino acids and brain serotonin function; implications for stress-related affective changes", NEUROMOL MED, vol. 10, 2008, pages 247
MATSUNAGA-IRIE S ET AL.: "Serum ghrelin levels are higher in Caucasian men than Japanese men aged 40-49 years", DIABETES OBESITY METABOL, vol. 9, 2007, pages 591 - 593
MCINTOSH CHS; WIDENMAIER S; KIM SJ.: "Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide", VITAM HORM, vol. 80, 2009, pages 409 - 471
MEYER C; TALBOT M; TEEDE H.: "Effect of Implanon on insulin resistance in women with polycystic ovary syndrome", AU N Z J OBST GYN, vol. 45, 2005, pages 155 - 158
MICHELS KB; TRICHOPOULOS D; ROBINS JM; ROSNER BA; MANSON JE; HUNTER DJ ET AL.: "Birthweight as a risk factor for breast cancer", LANCET, vol. 348, 1996, pages 1542 - 1546
MOORMAN PG; TERRY PD.: "Consumption of dairy products and the risk of breast cancer: a review of the literature", AM J CLIN NUTR, vol. 80, 2004, pages 5 - 14
NATURE, vol. 402, 1999, pages 656 - 660
NILSSON M; HOLST JJ; BJORCK IM.: "Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks", AM J CLIN NUTR, vol. 85, 2007, pages 996 - 1004
NORAT T; DOSSUS L; RINALDI S; OVERVARD K; GRONBAEK H; TJONNELAND A ET AL.: "Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women", EUR J CLIN NUTR, vol. 61, 2007, pages 91 - 98
OAKES SR; HYNES KM; WATERS MJ; HERINGTON AC; WERTHER GA.: "Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts", J CLIN ENDORCRINOL METAB, vol. 75, 1992, pages 1368 - 1373
OGILVY-STUART AL; HANDS SJ; ADCOCK CJ; HOLLY JM; MATTHEWS DR; MOHAMED-ALI V ET AL.: "Insulin, insulin-like growth factor I (IGF-I), IGF-binding protein-1, growth hormone, and feeding in the newborn", J CLIN ENDOCR METAB, vol. 83, 1998, pages 3550 - 3557
OLSEN SF; HALLDORSSON TI; WILLETT WC; KNUDSEN VK; GILMAN MW; MIKKELSEN TB ET AL.: "Milk consumption during pregnancy is associated with increased infant size at birth: prospective cohort study", AM J CLIN NUTR, vol. 86, 2007, pages 1104 - 1110
ONK KK; DIDERHOLM B; SALZANO G ET AL.: "Pregnancy insulin, glucose, and BMI contribute to birth outcomes in nondiabetic mothers", DIABETES CARE, vol. 31, 2008, pages 2193 - 2197
OSTMAN EM; LILJ BERG ELMSTAHL HGM ET AL.: "Inconsistency between glycemic and insulinemic reponses to regular and fermented milk products", AM J CLIN NUTR, vol. 74, 2001, pages 96 - 100
OSTMAN EM; LILJEBERG ELMSTAHL HGM; BJORCK IME.: "Inconsistency between glycemic and insulinemic responses to regular and fermented milk products", AM J CLIN NUTR, vol. 74, 2001, pages 96 - 100
PARODI PW.: "Dairy product consumption and the risk of breast cancer", J AM COLL NUTR, vol. 6, 2005, pages 556S - 568S
PATEL B; SCHUTTE R; SPORNS P; DOYLE J; JEWEL L; FEDORAK RN.: "Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease", INFLAMM BOWEL DIS, vol. 8, 2002, pages 340 - 346
PLANT TM; BARKER-GIBB MI.: "Neurobiological mechanisms of puberty in higher primates", HUM REPROD UPDATE, vol. 10, 2004, pages 67 - 77
POPHAM RE; SCHMIDT W; ISRAEL Y.: "Variation in mortality from ischemic heart disease in relation to alcohol and milk consumption", MED HYPOTHESES, vol. 12, 1983, pages 321 - 329
PUGLIELLI L.: "Aging of the brain, neurotrophin signaling, and Alzheimer's disease: Is IGF1-R the common culprit?", NEUROBIOLOGY OF AGING, vol. 29, 2008, pages 795 - 811
QIN LQ; HE K; XU JY.: "Milk consumption and circulating insulin-like growth factor-I level : a systematic literature review", INT J FOOD SCI NUTR., 11 September 2009 (2009-09-11)
QIN LQ; XU JY; TEZUKA H; WANG PY; HOSHI K.: "Milk inhibits the regression of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized rats", NUTR CANCER, vol. 60, 2008, pages 505 - 510
QIN LQ; XU JY; WANG PY; GANMAA D; LI J; KANEKO T ET AL.: "Low-fat milk promotes the development of 7,12-dimethylbenz(A)anthracene (DMBA)-induced mammary tumors in rats", INT J CANCER, vol. 110, 2004, pages 491 - 496
RESNICOFF M; BASEGA R.: "The role of insulin-like growth factor I receptor in transformation and apoptosis", ANN NY ACAD SCI, vol. 842, 1998, pages 76 - 81
RICH-EDWARDS JW; GANMAA D; POLLAK MN; NAKAMOTO EA; KLEINMAN K; TSERENDOLGOR U ET AL.: "Milk consumption and the prepubertal somatotropic axis", NUTR J, vol. 6, 2007, pages 28
ROCHE JR ET AL.: "Short communication: genetic selection for milk production increases plasma ghrelin in dairy cows", J DAIRY SCI, vol. 89, 2006, pages 3471 - 3475
ROGERS IS; GUNNELL D; EMMETT PM; GLYNN LR; DUNGER DB; HOLLY JM.: "Cross-sectional associations of diet and insulin-like growth factor levels in 7- to 8-year-old children", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 14, 2005, pages 204 - 212
ROSSKAMP R; BECKER M; SOETADJI S.: "Circulating somatomedin-C levels and the effect of growth hormone-releasing factor on levels of growth hormone and somatostatin-like inmmunoreactivity in obese children", EUR J PEDIATR, vol. 146, 1987, pages 48 - 50
RUDMAN SM; PHILPOTT MP; THOMAS GA; KEALEY T.: "The role of IGF-I in human skin and its appendages: morphogen as well as mitogen?", J INVEST DERMATOL, vol. 109, 1997, pages 770 - 777
SAVINO F ET AL.: "Ghrelin, leptin and IGF-1 levels in breast-fed and formula fed infants in the first years of life", ACTA PAEDIATRICA, vol. 94, 2005, pages 531 - 537
SCHERNHAMMER ES.: "In-utero exposures and breast cancer risk: joint effects of estrogens and insulin-like growth factor?", CANCER CAUSES CONTROL, vol. 13, 2002, pages 505 - 558
SEELY S.: "Diet and coronary disease: a survey of mortality rates and food consumption statistics of 24 countries", MED HYPOTHESES, vol. 7, 1981, pages 907 - 918
SFERRUZZI-PERRI AN; OWENS JA; STANDEN P; ROBERTS CT.: "Maternal insulin-like growth factor-II promotes placental functional development via the type 2 IGF receptor in the guinea pig", PLACENTA, vol. 29, 2008, pages 347 - 355
SFERRUZZI-PERRI AN; OWENS JA; STANDEN P; TAYLOR RL; ROBINSON JS; ROBERTS CT.: "Early pregnancy maternal endocrine insulin-like growth factor I programs the placenta for increased functional capacity throughout gestation", ENDOCRINOLOGY, vol. 148, 2007, pages 4362 - 4370
SHEARMAN LP ET AL.: "Ghrelin neutralization by a ribolnucleic acid-SPM ameliorates obesity in diet-induced obese mice", ENDOCRINOLOGY, vol. 147, 2006, pages 1517 - 1526
SORENSEN HT; SABROE S; ROTHMAN KJ; GILLMAN M; FISCHER P; SORENSEN TI.: "Relation between weight and length at birth and body mass index in young adulthood: corhort study", BMJ, vol. 315, 1997, pages 1137
SUTCLIFFE S; GIOVANNUCCI E; ISAACS WB; WILLETT WC; PLATZ EA: "Acne and risk of prostate cancer", INT J CANCER, vol. 121, 2007, pages 2688 - 2692
TAGUCHI A; WHITE MF: "Insulin-like signaling, nutrient homeostasis, and life span", ANN REV PHYSIOL, vol. 70, 2008, pages 191 - 212
TAMINI RM; COX DG; KRAFT P; POLLAK MN; HAIMAN CA; FREEDMAN ML ET AL.: "Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study", BREAST CANCER RES, vol. 9, 2007, pages R18
THIERRY VAN DESSEL HJ; LEE PD; FAESSEN G, FAUSER BC; GIUDICE LC.: "Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome", J CLIN ENDOCRINOL METABOL, vol. 84, 1999, pages 3030 - 3035
VALDES C; HELKIND-HIRSCH K.: "Intravenous glucose tolerance test- derived insulin sensitivity changes during the menstrual cycle", J CLIN ENDOCRINOL METAB, vol. 72, 1991, pages 642 - 645
VERDU EF; ARMSTRONG D; MURRAY JA.: "Between celiac disease and irritable bowel syndrome: The "no man's land" of gluten sensitivity", AM J GASTROENTEROL, ONLINE PUBLICATION, 19 May 2009 (2009-05-19)
VORA S; OVHAL A; JERAJANI H; NAIR N; CHAKRABORTTY A.: "Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne", BR J DERMATOL, vol. 159, 2008, pages 979 - 995
WABITSCH M; BLUM WF; MUCHE R; HEINZE E; HAUG C; MAYER H ET AL.: "Insulin-like growth factors and their binding proteins before and after weigth loss and their association with hormonal and metabolic parameters in obese adolescent girls", INT J OBES, vol. 20, 1996, pages 1073 - 1080
WABITSCH M; HAUNER H; HEINZE E; TELLER WM.: "The role of growth hormone/insulin-like growth factors in adipocyte differentiation", METABOLISM, vol. 44, 1995, pages 45 - 49
WELT CK; CHAN JL; BULLEN J; MURPHY R; SMITH P; DEPAOLI AM ET AL.: "Recombinant human leptin in women with hypothalamic amenorrhea", N ENGL J MED, vol. 351, 2004, pages 987 - 997
XUE F; MICHELS KB.: "Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence", LANCET ONCOL, vol. 8, 2007, pages 1088 - 1100
YANG SW; YU JS.: "Relationship of insulin-like growth factor-I, insulin-like growth factor binding protein-3, insulin, growth hormone in cord blood and maternal factors with birth height and birthweight", PEDIATR INTERNATIONAL, vol. 42, 2000, pages 31 - 36
YOSHIMURA Y.: "Insulin-like growth factors and ovarian physiology", J OBSTET GYNAECOL RES, vol. 24, 1998, pages 305 - 323
ZHU B; ZHAO G; WITTE D; HUI D; FAGIN JA: "Targeted overexpression of IGF1 in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury", ENDOCRINOLOGY, vol. 142, 2001, pages 3598 - 3606

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078974A1 (fr) * 2013-11-29 2015-06-04 Nestec S.A. Nutriment pour nourrisson pour améliorer la sensibilité à l'insuline au cours de la vie future
CN105578904A (zh) * 2013-11-29 2016-05-11 雀巢产品技术援助有限公司 用于改善后期生活中胰岛素敏感性的婴儿营养
RU2694827C1 (ru) * 2013-11-29 2019-07-17 Нестек С.А. Детское питание для улучшения чувствительности к инсулину в дальнейшей жизни
US10821150B2 (en) 2013-11-29 2020-11-03 Societe Des Produits Nestle S.A. Infant nutrition for improvement in insulin sensitivity later in life

Also Published As

Publication number Publication date
WO2010119088A3 (fr) 2011-06-30

Similar Documents

Publication Publication Date Title
Melnik Milk–the promoter of chronic Western diseases
Möllers et al. Metabolic-endocrine disruption due to preterm birth impacts growth, body composition, and neonatal outcome
Melnik Evidence for acne-promoting effects of milk and other insulinotropic dairy products
Melnik Milk consumption: aggravating factor of acne and promoter of chronic diseases of Western societies
Alexe et al. Determinants of early life leptin levels and later life degenerative outcomes
Agostoni et al. Is cow's milk harmful to a child's health?
Koletzko et al. Growth, development and differentiation: a functional food science approach
Melnik et al. Acne: risk indicator for increased body mass index and insulin resistance
Guilloteau et al. Adverse effects of nutritional programming during prenatal and early postnatal life, some aspects of regulation and potential prevention and treatments
Plagemann et al. Early postnatal life as a critical time window for determination of long-term metabolic health
Wren et al. Ghrelin enhances appetite and increases food intake in humans
Blättler et al. Feeding colostrum, its composition and feeding duration variably modify proliferation and morphology of the intestine and digestive enzyme activities of neonatal calves
Long et al. Multigenerational effects of fetal dexamethasone exposure on the hypothalamic–pituitary–adrenal axis of first-and second-generation female offspring
Hoeflich et al. Functional analysis of the IGF-system in milk
Symonds et al. Adipose tissue development during early life: novel insights into energy balance from small and large mammals
MX2011010454A (es) Mejoramiento en la promocion de la sana recuperacion del crecimiento.
Elmlinger et al. Insulin-like growth factors and binding proteins in early milk from mothers of preterm and term infants
Louise et al. The effect of preterm birth on adiposity and metabolic pathways and the implications for later life
Souza et al. Does early weaning shape future endocrine and metabolic disorders? Lessons from animal models
Teller et al. Complex lipid globules in early-life nutrition improve long-term metabolic phenotype in intra-uterine growth-restricted rats
Bittrich et al. Preterm as compared with full-term neonatal calves are characterized by morphological and functional immaturity of the small intestine
WO2001000047A1 (fr) Complements alimentaires prophylactiques a base de lait
Schmidt et al. Combined ACTH and glucocorticoid treatment improves survival and organ maturation in premature newborn calves
Wang et al. New insights into dairy management and the prevention and treatment of osteoporosis: the shift from single nutrient to dairy matrix effects—a review
WO2010119088A2 (fr) Lait et produits lactés modifiés pour présenter un indice insulinémique réduit et/ou une activité mitogène réduite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10713951

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10713951

Country of ref document: EP

Kind code of ref document: A2